secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2025-10-09T23:59:59+00:00
Accession:  0001829126-25-007973
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc subsidiary NuroMENA signs MSA with M42's IROS for UAE Phase 2b/3 trial of NEO100; board expanded
--------------------------------------------------------------------------------

- MSA with IROS (affiliate of M42 and Mubadala) covers clinical research services in UAE for CNS cancer therapies.
- First work order: Phase 2b/3 study of intranasal NEO100 in progressive/recurrent GBM and Grade III astrocytomas.
- Estimated budget of $2.4M in service fees plus $0.1M pass-through costs, milestone-based payments.
- NuroMENA board expands with Waleed K. Al Ali (CEO of Quazar Investment) and its Chairman, alongside Amir Heshmatpour and others.
- Company retains all IP and data from studies under MSA; agreement governed by Abu Dhabi Global Market law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625007973/0001829126-25-007973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625007973/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-007973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer